RGEN vs A vs QGEN Stock Comparison

Repligen, Agilent Technologies and Qiagen Prices as of Nov 13, 2026 Peers: Industry group
RGEN Repligen Corp
$167.79 -5.8% 1M +11.4% 1Y
Market cap
$9.16B
P/E
–
Revenue (TTM)
$805.61M
Div. yield
–
Life Sciences Tools Healthcare
2 wins
A Agilent Technologies, Inc.
$173.91 -0.1% 1M +18.4% 1Y
Market cap
$48.53B
P/E
33.7x
Revenue (TTM)
$7.37B
Div. yield
0.01%
Life Sciences Tools Healthcare
6 wins
QGEN Qiagen N.V.
$49.90 +9.6% 1M +6.2% 1Y
Market cap
$10.81B
P/E
28.1x
Revenue (TTM)
$2.12B
Div. yield
–
Life Sciences Tools Healthcare
3 wins

Head to Head

11 decided of 12

Agilent Technologies leads on 6 of the 12 questions below (Agilent Technologies 6, Qiagen 3, Repligen 2). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionRGENAQGENLeader
Larger companyMarket capitalisation $9.16B $48.53B $10.81B A
Cheaper on earningsLower P/E, profitable companies only -775.9x 33.7x 28.1x QGEN
Cheaper on forward earningsLower price / next fiscal year consensus EPS 86.0x 26.6x 21.2x QGEN
Faster revenue growthRevenue growth, trailing twelve months +13.8% +8.6% +2.2% RGEN
More profitableNet margin, trailing twelve months -1.5% 19.5% 18.2% A
Better return on capitalReturn on invested capital 0.0% 13.1% 7.4% A
Less leveragedLower net debt / EBITDA -2.8x 1.1x 1.2x RGEN
Higher dividend yieldTrailing dividend yield 0.00% 0.01% 0.00% –
Better 1-year returnPrice return, last 12 months +11.4% +18.4% +6.2% A
Better 5-year returnAnnualised price return, 5 years -8.3%/yr +1.6%/yr -3.6%/yr A
Less volatileAnnualised volatility, 1 year 46.5% 32.8% 35.2% A
Higher overall scoreMean of the five percentile scores vs peers 58/100 61/100 69/100 QGEN

Percentile Scorecard

RGENAQGEN

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisRGENAQGEN
Valuation 56 #108 of 243 60 #98 of 243 74 #63 of 243
Growth 30 #161 of 228 37 #144 of 228 25 #171 of 228
Profitability 67 #75 of 222 93 #17 of 222 93 #16 of 222
Financial Health 80 #50 of 248 53 #117 of 248 60 #100 of 248
Shareholder Returns 57 #68 of 158 64 #57 of 158 94 #11 of 158
Overall 58 61 69
  • RGEN ranked among 252 companies in Medical Devices and Diagnostics
  • A ranked among 252 companies in Medical Devices and Diagnostics
  • QGEN ranked among 252 companies in Medical Devices and Diagnostics

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodRGENAQGENSPY
1 month -5.8%-0.1%+9.6% -2.0%
3 months +0.6%+17.1%+16.2% -2.8%
6 months +63.1%+55.7%+51.3% +2.0%
Year to date +2.4%+27.8%+5.4% +10.6%
1 year +11.4%+18.4%+6.2% +12.2%
3 years +9.1%+55.8%+13.0% +68.1%
3 years, per year +2.9%+15.9%+4.2% +18.9%
5 years -35.1%+8.1%-16.9% +61.4%
5 years, per year -8.3%+1.6%-3.6% +10.1%
10 years +419.6%+275.0%+56.5% +248.5%
10 years, per year +17.9%+14.1%+4.6% +13.3%

Risk

MeasureRGENAQGENSPY
Volatility, 1Y 46.5%32.8%35.2% 13.6%
Downside volatility, 1Y 47.4%28.1%29.7% 13.9%
Beta vs S&P 500, 1Y 1.210.910.38 1.00
Return / volatility, 1Y 0.250.560.18 0.90
Max drawdown, 5Y -64.7%-39.6%-48.2% -25.4%
From 52-week high -13.8%-4.2%-10.3% -3.2%
52-week high $194.57$181.54$55.66 $779.14
52-week low $102.87$110.24$32.63 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleRGENAQGEN
P/E now vs peer median -804.0xmedian 26.5x 34.1xmedian 26.5x 28.2xmedian 26.5x
P/S now vs peer median 11.8xmedian 2.7x 6.7xmedian 2.7x 5.1xmedian 2.7x
EV/EBITDA now vs peer median 83.9xmedian 18.4x 26.8xmedian 18.4x 17.7xmedian 18.4x
P/FCF now vs peer median 89.1xmedian 25.4x 38.7xmedian 25.4x 11.2xmedian 25.4x
P/B now vs peer median 4.5xmedian 2.5x 6.7xmedian 2.5x 3.1xmedian 2.5x
PEG now vs peer median 28.28median 0.98 3.46median 0.98 11.74median 0.98

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsRGENAQGEN
Revenue $805.61M $7.37B $2.12B
Gross profit $430.67M $3.97B $1.33B
Operating income $18.24M $1.64B $448.74M
Net income -$11.80M $1.44B $384.93M
Free cash flow $106.72M $1.27B $964.47M
R&D $57.23M $485.00M $199.87M
EPS (diluted) $-0.21 $5.09 $1.76
Cash & equivalents $726.96M $1.76B $805.13M
Total debt $555.60M $3.95B $1.64B
Shares (diluted) 56.56M 283.00M 218.88M
Enterprise value $5.93B $41.42B $7.44B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricRGENAQGEN
P/E -804.0x 34.1x 28.2x
P/FCF 89.1x 38.7x 11.2x
P/Operating cash flow 73.2x 30.5x 17.0x
P/S 11.8x 6.7x 5.1x
P/B 4.5x 6.7x 3.1x
P/Tangible book 5.3x 7.6x 3.4x
EV/EBITDA 83.9x 26.8x 17.7x
EV/EBIT 504.7x 31.3x 25.9x
EV/Revenue 11.4x 6.9x 5.5x
EV/FCF 86.3x 40.4x 12.1x
EV/Operating cash flow 70.9x 31.8x 18.3x
PEG (3Y EPS CAGR) 28.28 3.46 11.74

Growth

14 metrics
MetricRGENAQGEN
Revenue growth (1Y) 13.8% 8.6% 2.2%
Revenue CAGR (3Y) 7.3% 1.8% 2.7%
Gross profit growth (1Y) 33.0% 11.2% 1.7%
Gross profit CAGR (3Y) 13.3% 3.7% 2.5%
Operating income growth (1Y) 2,185% 13.5% -7.6%
Operating income CAGR (3Y) -40.5% 5.1% 3.6%
Net income growth (1Y) -779.2% 18.0% -2.8%
Net income CAGR (3Y) -28.4% 8.3% 5.0%
EPS growth (1Y) -778.9% 18.9% -7.3%
EPS CAGR (3Y) -28.4% 9.8% 2.4%
Operating cash flow growth (1Y) -0.8% 7.6% -3.4%
Operating cash flow CAGR (3Y) 5.3% -1.9% 13.7%
Free cash flow growth (1Y) -3.0% 16.5% 1.1%
Free cash flow CAGR (3Y) 17.6% -3.7% 13.5%

Profitability

14 metrics
MetricRGENAQGEN
Gross margin 53.5% 53.8% 62.8%
EBITDA margin 13.6% 25.9% 31.0%
Operating margin 2.3% 22.2% 21.2%
Pretax margin 1.0% 22.5% 21.7%
Net margin -1.5% 19.5% 18.2%
FCF margin 13.2% 17.2% 45.6%
Operating cash flow margin 16.1% 21.8% 30.0%
Return on equity -1.7% 19.9% 11.3%
Return on assets -1.2% 10.7% 6.5%
Return on invested capital 0.0% 13.1% 7.4%
Return on capital employed 0.6% 14.6% 8.5%
Asset turnover 0.3x 0.5x 0.4x
Cash conversion (OCF / net income) -11.0x 1.1x 1.6x
Stock comp / revenue 4.2% 1.8% 2.0%

Financial Health

11 metrics
MetricRGENAQGEN
Debt / assets 19.0% 28.3% 27.6%
Debt / equity 0.3x 0.5x 0.5x
Net debt / EBITDA -2.8x 1.1x 1.2x
Debt / FCF 5.2x 3.1x 1.7x
Liabilities / assets 28.5% 47.3% 41.5%
Equity / assets 71.5% 52.7% 58.5%
Interest coverage 0.8x 15.5x 10.8x
Current ratio 9.9x 2.1x 2.6x
Quick ratio 8.1x 1.4x 1.9x
Cash ratio 6.9x 0.8x 1.3x
Altman Z-score 7.80 5.77 4.14

Shareholder Returns

7 metrics
MetricRGENAQGEN
Dividend yield – 0.6% 5.3%
Net buyback yield -0.2% 0.6% 0.6%
Shareholder yield -0.2% 1.2% 5.9%
Payout ratio (earnings) – 19.9% –
Payout ratio (FCF) – 22.6% –
Dividend growth (1Y) – 2.1% –
Dividend CAGR (3Y) – 3.1% –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusRGENAQGEN
Forward P/E 86.0xFY2026 26.6xFY2026 21.2xFY2026
EPS, next fiscal year $1.95FY2026 $6.54FY2026 $2.35FY2026
EPS growth, next FY +14.0%FY2026 +17.0%FY2026 -1.3%FY2026
EPS growth, the year after +29.2% +0.2% +17.9%
Revenue, next fiscal year $791.31MFY2026 $7.87BFY2026 $2.25BFY2026
Revenue growth, next FY +7.2%FY2026 +15.3%FY2026 +7.8%FY2026
Revenue growth, the year after +44.3% -5.6% -2.8%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersRGENAQGEN
Held by institutions 100.0% 92.6% 67.3%
Institutions holding 483 1,126 338
Change in shares held, QoQ +1.2% +3.2% +16.5%
Institutions buying 273 601 216
Institutions selling 141 351 86
Buyers to sellers 1.94 1.71 2.51

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

RGENAQGEN
RGEN 1.00 0.63 0.37
A 0.63 1.00 0.37
QGEN 0.37 0.37 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, RGEN, A and QGEN?

Agilent Technologies (A) is the largest by market capitalisation: Repligen (RGEN) $9.16B, Agilent Technologies (A) $48.53B, Qiagen (QGEN) $10.81B.

Which stock is cheaper, RGEN, A and QGEN?

Qiagen (QGEN) trades on the lowest price-to-earnings ratio (Repligen (RGEN) -775.9x, Agilent Technologies (A) 33.7x, Qiagen (QGEN) 28.1x). On next year's consensus earnings, Qiagen (QGEN) is cheapest (Repligen (RGEN) 86.0x, Agilent Technologies (A) 26.6x, Qiagen (QGEN) 21.2x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

Repligen (RGEN) grew revenue fastest over the trailing twelve months: Repligen (RGEN) +13.8%, Agilent Technologies (A) +8.6%, Qiagen (QGEN) +2.2%.

Which company is more profitable?

Agilent Technologies (A) has the highest net margin (Repligen (RGEN) -1.5%, Agilent Technologies (A) 19.5%, Qiagen (QGEN) 18.2%). On return on invested capital, Agilent Technologies (A) leads (Repligen (RGEN) 0.0%, Agilent Technologies (A) 13.1%, Qiagen (QGEN) 7.4%).

Which stock has performed better?

Over the past year Agilent Technologies (A) returned the most: Repligen (RGEN) +11.4%, Agilent Technologies (A) +18.4%, Qiagen (QGEN) +6.2%. Over five years, Agilent Technologies (A) compounded fastest (Repligen (RGEN) -8.3%/yr, Agilent Technologies (A) +1.6%/yr, Qiagen (QGEN) -3.6%/yr). Returns are price only, before dividends.

Which pays a higher dividend?

Only one of these companies pays a dividend: Repligen (RGEN) 0.00%, Agilent Technologies (A) 0.01%, Qiagen (QGEN) 0.00%. Repligen (RGEN) and Qiagen (QGEN) pays no regular dividend.

Which stock is riskier?

By one-year price volatility, Agilent Technologies (A) has been the steadiest (Repligen (RGEN) 46.5%, Agilent Technologies (A) 32.8%, Qiagen (QGEN) 35.2%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, RGEN, A and QGEN?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Agilent Technologies (A) leads on 6. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.